The results reveal that the c-MET receptor is the promising protein target of HNC018, with a binding energy of −9.2 kcal/mol and a binding distance of 3.2 Å to the ASN1167 residue, 3.7 Å to the ASP1164 residue, and 3.9 Å to MET1211 of the receptor; this is comparable to the binding affinity of −8.8 kcal/mol obtained when c-MET was docked with Crizotinib, a known HNSCC inhibitor (Figure 8A and Table 3). This evidence concerns the gene MET and head and neck squamous cell carcinoma.